Turn Bio Adds Veteran Executives with Decades of International Business Development, Intellectual Property Expertise
PR94854
MOUNTAIN VIEW, Calif., Mar. 7, 2022 /PRNewswire=KYODO JBN/--
-- Hires will help to expand Turn's commercial reach, protect its unique ERA
Platform technology
Turn Biotechnologies, a cell rejuvenation company developing novel mRNA
medicines to cure now-untreatable, chronic, age-related conditions, today
announced the addition of global expertise in partnership development and
intellectual property protection.
Turn has hired two executives with deep experience that will help to maximize
the company's commercial reach through the development of international
partnerships and preserve its value by protecting its proprietary science,
including its break-through ERA Platform technology.
Marie-Louise Bots, an executive with broad global expertise and a record of
strategic transformation in Fortune 500 corporations and venture-backed firms,
was named senior vice president of corporate and business development. She will
oversee Turn's efforts to develop strategic partnerships with healthcare,
insurance and financial companies, around the world.
Throughout her career, she has provided strategic leadership to companies such
as Rotterdam-based Aon Risk Solutions, where she served as chief commercial
officer and transformed the commercial organization, developing and driving its
strategy.
She founded Philips Royal Electronics' Skincare Division and drove its embrace
of innovative technology while creating partnerships and managing the
division's acquisitions and joint ventures. At Philips, she also accelerated
critical changes in the Oral Healthcare Division by acquiring Sonicare.
Bots has a degree in Economics from Fontys University of Applied Sciences in
Eindhoven, Netherlands, and has studied at Erasmus University in Rotterdam and
Babson College in Boston.
Dr. Devang Thakor, a corporate and patent attorney, has been named vice
president of intellectual property and legal. Thakor granted more than 130
pharmaceutical and biotechnology patents in a decade as a U.S. patent examiner,
including four years as a primary examiner, and has advised Global 500
companies, international startups, venture capital firms and universities on
intellectual property and business issues.
Thakor's hands-on experience at the U.S. Patent and Trademark Office provides
novel and practical perspectives on the processes companies must follow to
protect their intellectual property. His work with companies in North America
and Asia gives him unique understanding of the nuances that must be negotiated
as they enter markets with diverse intellectual property protection
regulations.
He also brings technical expertise to Turn's intellectual property strategy,
having developed nucleic acid delivery and regenerative medicine technologies
in postdoctoral fellowships at Harvard Medical School, the VA Boston Healthcare
System and Kyoto University.
"The expertise that Marie-Louise and Devang bring to Turn is critical to our
long-term growth strategy," said Turn CEO Anja Krammer. "Our cutting-edge
science has the potential to change the lives of millions of people afflicted
with age-related conditions that medicine cannot treat today. Their experience
will help to grow and protect our value for investors, while speeding our
commercial reach through global business partnerships."
ABOUT TURN BIOTECHNOLOGIES
Turn is a pre-clinical-stage company focused on repairing tissue at the
cellular level. The company's proprietary mRNA platform technology, ERA™,
combats the effects of aging in the epigenome, thus restoring optimal gene
expression and enabling cells to function as vigorously as when they were
younger. This restores the cells' ability to prevent or treat disease and heal
or regenerate tissue and will help to fight incurable chronic diseases.
Turn's technology provides a platform from which to attack a variety of now
incurable chronic diseases. The company is currently completing pre-clinical
research on tailored therapies targeting indications in dermatology and
immunology, as well as developing therapies for ophthalmology, osteo-arthritis
and the muscular system. For more information, visit: www.turn.bio .
For more information contact:
Jim Martinez, rightstorygroup, jim@rightstorygroup.com or +1-312-543-9026
SOURCE: Turn Biotechnologies
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。